1. Home
  2. TBHC vs TENX Comparison

TBHC vs TENX Comparison

Compare TBHC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBHC
  • TENX
  • Stock Information
  • Founded
  • TBHC 1966
  • TENX 1967
  • Country
  • TBHC United States
  • TENX United States
  • Employees
  • TBHC N/A
  • TENX N/A
  • Industry
  • TBHC Other Specialty Stores
  • TENX Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBHC Consumer Discretionary
  • TENX Health Care
  • Exchange
  • TBHC Nasdaq
  • TENX Nasdaq
  • Market Cap
  • TBHC 27.6M
  • TENX 25.8M
  • IPO Year
  • TBHC N/A
  • TENX N/A
  • Fundamental
  • Price
  • TBHC $1.28
  • TENX $5.90
  • Analyst Decision
  • TBHC
  • TENX Strong Buy
  • Analyst Count
  • TBHC 0
  • TENX 3
  • Target Price
  • TBHC N/A
  • TENX $16.00
  • AVG Volume (30 Days)
  • TBHC 406.0K
  • TENX 23.2K
  • Earning Date
  • TBHC 09-04-2025
  • TENX 08-19-2025
  • Dividend Yield
  • TBHC N/A
  • TENX N/A
  • EPS Growth
  • TBHC N/A
  • TENX N/A
  • EPS
  • TBHC N/A
  • TENX N/A
  • Revenue
  • TBHC $431,111,000.00
  • TENX N/A
  • Revenue This Year
  • TBHC N/A
  • TENX N/A
  • Revenue Next Year
  • TBHC N/A
  • TENX N/A
  • P/E Ratio
  • TBHC N/A
  • TENX N/A
  • Revenue Growth
  • TBHC N/A
  • TENX N/A
  • 52 Week Low
  • TBHC $1.20
  • TENX $3.25
  • 52 Week High
  • TBHC $1.73
  • TENX $7.89
  • Technical
  • Relative Strength Index (RSI)
  • TBHC N/A
  • TENX 38.15
  • Support Level
  • TBHC N/A
  • TENX $5.78
  • Resistance Level
  • TBHC N/A
  • TENX $6.25
  • Average True Range (ATR)
  • TBHC 0.00
  • TENX 0.23
  • MACD
  • TBHC 0.00
  • TENX -0.05
  • Stochastic Oscillator
  • TBHC 0.00
  • TENX 3.96

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: